Lisata Therapeutics Inc. (LSTA)
NasdaqCM: LSTA
· Real-Time Price · USD
1.18
-0.03 (-2.48%)
At close: Aug 12, 2026, 3:59 PM
1.18
+0.00%
After-hours: 4:10 PM
Lisata Therapeutics Inc. (LSTA) Stock Price, Analysis & Data
-2.48% (1D)
| Bid | 2.21 |
| Market Cap | 10.63M |
| Revenue (ttm) | 100K |
| Net Income (ttm) | -14.62M |
| Beta | n/a |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.02 |
| P/B (ttm) | 0.98 |
| P/S (ttm) | 106.33 |
| Earnings Date | Nov 5, 2026 |
| Ask | 1.05 |
| Volume | 37,577 |
| Avg. Volume (20D) | 126,770 |
| Open | 1.28 |
| Previous Close | 1.21 |
| Day's Range | 1.12 - 1.28 |
| 52-Week Range | 0.99 - 5.07 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 1999
Employees 21
Stock Exchange NasdaqCM
Ticker Symbol LSTA
Website https://www.lisata.com
Financial Performance
In 2025, Lisata Therapeutics's revenue was 170K, a decrease of -83% compared to the previous year's 1M. Earnings were -16.59M, a decrease of -17.01%.
Financial StatementsEarnings Surprise
Lisata Therapeutics has released their quarterly earnings on Nov 6, 2025:
Lisata Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2